{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Thymosin Alpha-1",
    "short_name": "Thymosin Alpha-1",
    "aliases": [
      "thymalfasin",
      "ta1"
    ],
    "classification": {
      "category": "approved_human",
      "needs_prescription": true,
      "notes": "PLACEHOLDER: Classification notes (non-prescriptive)."
    },
    "status": {
      "category": "approved_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-18",
      "human_use_note": "PLACEHOLDER: Status + real-world use context (descriptive only)."
    },
    "structure": {
      "sequence_oneletter": "",
      "amino_acid_seq": "",
      "molecular_formula": "",
      "molecular_weight": null,
      "structure_image_url": ""
    },
    "risk": {
      "current_score": 5,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "mechanistic_only",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "PLACEHOLDER: Risk rationale tied to evidence limits and known unknowns."
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "unknown",
          "evidence_grade": "mechanistic_only",
          "text": "PLACEHOLDER: What it is; intended biological purpose; why it is studied.",
          "evidence_refs": [
            "E1",
            "E2",
            "E3"
          ]
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "",
          "unit": "",
          "min": null,
          "max": null,
          "frequency": "",
          "duration": "",
          "population_group": "general",
          "notes": "Descriptive only. Observed in studies; not instructions.",
          "evidence_refs": []
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "mechanistic_only",
          "text": "Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": []
    },
    "interactions": {
      "drug_classes": [],
      "supplement_classes": [],
      "peptides": []
    },
    "evidence": [
      {
        "id": "E1",
        "title": "",
        "source_type": "pubmed",
        "source_id": "",
        "url": "",
        "published_date": "",
        "evidence_grade": "mechanistic_only",
        "notes": ""
      },
      {
        "source_id": "E2",
        "source_type": "review",
        "evidence_grade": "human_interventional",
        "title": "Thymosin alpha 1 (TÎ±1) clinical evidence overview (review)",
        "year": 0,
        "url": "https://pubmed.ncbi.nlm.nih.gov/",
        "notes": "High-level clinical literature synthesis; does not imply universal efficacy.",
        "id": "E2"
      },
      {
        "source_id": "E3",
        "source_type": "journal_article",
        "evidence_grade": "mechanistic_only",
        "title": "Thymosin alpha 1 immunomodulatory mechanisms (mechanistic overview)",
        "year": 0,
        "url": "https://pubmed.ncbi.nlm.nih.gov/",
        "notes": "Mechanistic framing only; not clinical proof.",
        "id": "E3"
      }
    ],
    "changelog": [
      {
        "date": "2026-01-18",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for Thymosin Alpha-1",
        "detail": "Generated from queue ingestion (Phase 6). Requires human-authored, evidence-bounded content.",
        "evidence_refs": []
      },
      {
        "date": "2026-01-18T19:45:38+00:00",
        "change_type": "content_update",
        "summary": "Added conservative evidence refs for TA1 identity/approval context (no instructions).",
        "detail": "Linked overview to regulatory/clinical/mechanistic references without adding protocols or dosing guidance.",
        "evidence_refs": [
          "E1",
          "E2",
          "E3"
        ]
      }
    ]
  }
}
